Alaunos Therapeutics TCRT Director, 10% owner · filings 2026 to 2026
No transactions in the filings read; Form 144 notices are listed above.
Person · CIK 1802528
Fairmount Funds Management
Director at Alaunos Therapeutics, Korsana Biosciences, Apogee Therapeutics, Crescent Biopharma, Oruka Therapeutics, Spyre Therapeutics, Jade Biosciences, Viridian Therapeutics, Zenas BioPharma, Cogent Biosciences and Damora Therapeutics
Earlier: Dianthus Therapeutics
Sold on Form 4$1.2B
Noticed on Form 144$1.2B
Bought on Form 4$230.6M
Companies12
Holdings now
As reported after the latest Form 3, 4 or 5 at each company.
How these figures work
Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.
| Company | Security | Held | Shares or units | As of |
|---|---|---|---|---|
| Alaunos Therapeutics TCRT | Common Stock | By Fairmount Healthcare Co-Invest VII L.P. | 687,789 | Oct 13, 2026 · Filing · EDGAR |
| Alaunos Therapeutics TCRT | Series B Preferred Stock into Common Stock | By Fairmount Healthcare Fund II L.P. | 105,286,000 | Oct 13, 2026 · Filing · EDGAR |
| Alaunos Therapeutics TCRT | Series C Preferred Stock into Common Stock | By Fairmount Healthcare Fund II L.P. | 52,239,000 | Oct 13, 2026 · Filing · EDGAR |
| Alaunos Therapeutics TCRT | Series C Preferred Stock into Common Stock | By Fairmount Healthcare Co-Invest VII L.P. | 16,725,000 | Oct 13, 2026 · Filing · EDGAR |
| Korsana Biosciences KRSA | Common Stock | By Fairmount Healthcare Fund II L.P. | 6,911,174 | Sep 8, 2026 · Filing · EDGAR |
| Korsana Biosciences KRSA | Common Stock | By Fairmount Healthcare Co-Invest VI L.P. | 2,192,555 | Sep 8, 2026 · Filing · EDGAR |
| Korsana Biosciences KRSA | Stock Option (Right to Buy) exercise $26.20, expires Sep 9, 2036, into Common Stock | By: Tomas Kiselak | 48,445 | Sep 9, 2026 · Filing · EDGAR |
| Crescent Biopharma CBIO | Ordinary Shares | By Fairmount Healthcare Fund II L.P. | 3,601,316 | Jul 16, 2026 · Filing · EDGAR |
| Crescent Biopharma CBIO | Pre-Funded Warrant (Right to Buy) exercise $0.00, into Ordinary Shares | By Fairmount Healthcare Fund II L.P. | 2,294,037 | Jul 16, 2026 · Filing · EDGAR |
| Oruka Therapeutics ORKA | Common Stock | By Fairmount Healthcare Co-Invest III L.P. | 2,573,308 | Jul 1, 2026 · Filing · EDGAR |
| Oruka Therapeutics ORKA | Common Stock | By Fairmount Healthcare Fund II L.P. | 1,131,954 | Jul 1, 2026 · Filing · EDGAR |
| Oruka Therapeutics ORKA | Series B Preferred Stock into Common Stock | By Fairmount Healthcare Fund II L.P. | 94,497 | Jul 1, 2026 · Filing · EDGAR |
| Spyre Therapeutics AGLE | Common Stock | By Fairmount Healthcare Fund II LP | 9,184,458 | Jun 22, 2023 · Filing · EDGAR |
| Spyre Therapeutics AGLE | Common Stock | By Tomas Kiselak | 406,038 | Jun 23, 2026 · Filing · EDGAR |
| Spyre Therapeutics AGLE | Common Stock | By Peter Harwin | 406,038 | Jun 23, 2026 · Filing · EDGAR |
| Spyre Therapeutics AGLE | Common Stock | By Fairmount Healthcare Fund LP( | 276,082 | Jun 22, 2023 · Filing · EDGAR |
| Spyre Therapeutics AGLE | Common Stock | By Fairmount Healthcare Fund L.P. | 11,043 | Nov 24, 2023 · Filing · EDGAR |
| Spyre Therapeutics AGLE | Series A Preferred Stock into Common Stock | Fairmount Healthcare Fund II LP | 346,045 | Jun 23, 2026 · Filing · EDGAR |
| Jade Biosciences JBIO | Common Stock | By Fairmount Healthcare Co-Invest IV L.P. | 2,655,817 | Oct 6, 2025 · Filing · EDGAR |
| Jade Biosciences JBIO | Common Stock | By Fairmount Healthcare Fund II L.P. | 1,897,677 | Oct 6, 2025 · Filing · EDGAR |
| Jade Biosciences JBIO | Stock Option (Right to Buy) exercise $15.22, expires Jun 8, 2036, into Common Stock | Directly | 34,843 | Jun 9, 2026 · Filing · EDGAR |
| Viridian Therapeutics MGEN | Common Stock | By Fairmount Healthcare Fund II L.P. | 5,090,928 | May 11, 2026 · Filing · EDGAR |
| Viridian Therapeutics MGEN | Common Stock | Fairmount Healthcare Fund II LP | 3,914,458 | Oct 23, 2025 · Filing · EDGAR |
| Viridian Therapeutics MGEN | Common Stock | By funds | 526,393 | Oct 27, 2020 · Filing · EDGAR |
| Zenas BioPharma ZBIO | Common Stock | By Fairmount Healthcare Fund II L.P. | 2,359,025 | Mar 31, 2026 · Filing · EDGAR |
| Zenas BioPharma ZBIO | Common Stock | By Fairmount Healthcare Fund II LP | 1,892,806 | Sep 16, 2024 · Filing · EDGAR |
| Zenas BioPharma ZBIO | Stock Option (Right to Buy) exercise $11.94, expires Jun 10, 2035, into Common Stock | By Tomas Kiselak | 18,500 | Jun 10, 2025 · Filing · EDGAR |
| Cogent Biosciences UMRX | Common Stock | Fairmount Healthcare Fund II LP | 5,503,418 | Mar 31, 2026 · Filing · EDGAR |
| Cogent Biosciences UMRX | Series A Convertible Preferred Stock into Common Stock | Fairmount Healthcare Fund II LP | 39,414 | Mar 31, 2026 · Filing · EDGAR |
| Damora Therapeutics GLTO | Common Stock | By Fairmount Healthcare Fund II L.P. | 5,809,000 | Feb 9, 2026 · Filing · EDGAR |
| Damora Therapeutics GLTO | Common Stock | By Fairmount Healthcare Co-Invest V L.P. | 2,904,000 | Feb 9, 2026 · Filing · EDGAR |
| Damora Therapeutics GLTO | Stock Option (right to buy) exercise $23.05, expires Mar 23, 2036, into Common Stock | By: Peter Harwin | 37,313 | Mar 23, 2026 · Filing · EDGAR |
| Dianthus Therapeutics | Common Stock | See footnote | 2,762,837 | Jan 22, 2024 · Filing · EDGAR |
| Dianthus Therapeutics | Common Stock | By Fairmount Healthcare Fund II LP | 2,700,691 | Apr 1, 2024 · Filing · EDGAR |
| Dianthus Therapeutics | Common Stock | By Fairmount Healthcare Fund II L.P. | 2,700,691 | Sep 27, 2024 · Filing · EDGAR |
| Dianthus Therapeutics | Stock Option (Right to Buy) exercise $21.77, expires May 22, 2034, into Common Stock | See footnote | 11,000 | May 23, 2024 · Filing · EDGAR |
Sold and noticed by quarter
Sold (Form 4) Noticed (Form 144) Bought (Form 4)
Quarterly totals as a table
| Quarter | Sold (Form 4) | Noticed (Form 144) | Bought (Form 4) |
|---|---|---|---|
| Q3 2026 | $300M | $300M | $12.4M |
| Q2 2026 | $399.7M | $399.7M | $20M |
| Q1 2026 | $503.5M | $503.5M | $3M |
| Q4 2025 | — | — | $34.2M |
| Q3 2025 | — | — | $25M |
| Q3 2024 | — | — | $35.1M |
| Q1 2024 | — | — | $10M |
| Q3 2023 | — | — | $51.4M |
| Q2 2023 | — | — | $9.6M |
| Q3 2022 | — | — | $10M |
| Q2 2022 | — | — | $9.9M |
| Q3 2021 | — | — | $10M |
Planned sales (Form 144) and the sales that followed
Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.
How we match
A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.
| Notice date | Noticed | Planned sale | Outcome | Links |
|---|---|---|---|---|
| Oruka Therapeutics ORKA · Goldman Sachs · No 10b5-1 plan stated · 1 notice | ||||
| Jul 1, 2026 | 3,553,410 · ~$300M | Jul 1, 2026 | Sold as noticed Sold 3,553,410 at $84.43 on Jul 1 · $300M Form 4 | Filing · EDGAR |
| Spyre Therapeutics AGLE · Goldman Sachs · No 10b5-1 plan stated · 1 notice | ||||
| Jun 23, 2026 | 4,684,781 · ~$399.7M | Jun 23, 2026 | Sold as noticed Sold 4,684,781 at $85.31 on Jun 23 · $399.7M Form 4 | Filing · EDGAR |
| Cogent Biosciences UMRX · Goldman Sachs · No 10b5-1 plan stated · 1 notice | ||||
| Mar 31, 2026 | 7,000,000 · ~$242.6M | Mar 31, 2026 | Sold as noticed Sold 7,000,000 at $34.66 on Mar 31 · $242.6M Form 4 | Filing · EDGAR |
| Cogent Biosciences UMRX · Jefferies · No 10b5-1 plan stated · 1 notice | ||||
| Jan 22, 2026 | 3,500,000 · ~$127.4M | Jan 22, 2026 | Sold as noticed Sold 3,500,000 at $36.40 on Jan 22 · $127.4M Form 4 | Filing · EDGAR |
| Apogee Therapeutics APGE · Jefferies · No 10b5-1 plan stated · 1 notice | ||||
| Jan 22, 2026 | 1,750,000 · ~$133.5M | Jan 22, 2026 | Sold as noticed Sold 1,750,000 at $76.30 on Jan 22 · $133.5M Form 4 | Filing · EDGAR |
Every transaction, by company
Each Form 3, 4 and 5 transaction in plain words, newest first.
How these figures work
Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.
Korsana Biosciences KRSA Director, 10% owner · filings 2026 to 2026
Apogee Therapeutics APGE Director · filings 2023 to 2026 · sold $133.5M · bought $50M · $133.5M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | Returned to the company | −340,855 | $135.11 | $46.1M | 0 By Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Sep 3, 2026 | Returned to the company | −51,166 | $135.11 | $6.9M | 0 By Tomas Kiselak | Filing · EDGAR |
| Sep 3, 2026 | Returned to the company | −51,166 | $135.11 | $6.9M | 0 By Peter Harwin | Filing · EDGAR |
| Sep 3, 2026 | Returned to the company Non-Voting Common Stock | −6,743,321 | 0 By Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Sep 3, 2026 | Returned to the company Stock Option (Right to Buy) | −47,758 | 0 By Tomas Kiselak | Filing · EDGAR | ||
| Sep 3, 2026 | Returned to the company Stock Option (Right to Buy) | −10,370 | 0 By Tomas Kiselak | Filing · EDGAR | ||
| Sep 3, 2026 | Returned to the company Stock Option (Right to Buy) | −14,461 | 0 By Tomas Kiselak | Filing · EDGAR | ||
| Sep 3, 2026 | Returned to the company Stock Option (Right to Buy) | −7,657 | 0 By Tomas Kiselak | Filing · EDGAR | ||
| Aug 7, 2026 | Option or RSU exercised or converted | +31,838 | $17.00 | $541K | 330,485 By Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Aug 7, 2026 | Option or RSU exercised or converted | +10,370 | $43.85 | $455K | 340,855 By Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Aug 7, 2026 | Option or RSU exercised or converted Stock Option (Right to Buy) | −31,838 | 0 direct | Filing · EDGAR | ||
| Aug 7, 2026 | Option or RSU exercised or converted Stock Option (Right to Buy) | −10,370 | 0 direct | Filing · EDGAR | ||
| Jun 9, 2026 | Grant or award from the company Stock Option (Right to Buy) | +7,657 | 7,657 By: Tomas Kiselak | Filing · EDGAR | ||
| Jan 22, 2026 | Open-market or private sale | −1,750,000 | $76.30 | $133.5M | 298,647 By Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Jun 17, 2025 | Grant or award from the company Stock Option (Right to Buy) | +14,461 | 14,461 By: Peter Harwin | Filing · EDGAR | ||
| Jun 17, 2025 | Grant or award from the company Stock Option (Right to Buy) | +14,461 | 14,461 By: Tomas Kiselak | Filing · EDGAR | ||
| Jun 5, 2024 | Grant or award from the company Stock Option (Right to Buy) | +10,370 | 10,370 direct | Filing · EDGAR | ||
| Jun 5, 2024 | Grant or award from the company Stock Option (Right to Buy) | +10,370 | 10,370 direct | Filing · EDGAR | ||
| Mar 28, 2024 | Other acquisition or disposition (see the filing) | −55,913 | 0 By Fairmount Healthcare Fund LP | Filing · EDGAR | ||
| Mar 28, 2024 | Other acquisition or disposition (see the filing) | +55,913 | 2,048,647 By Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Mar 28, 2024 | Other acquisition or disposition (see the filing) Non-Voting Common Stock | −221,426 | 0 By Fairmount Healthcare Fund LP | Filing · EDGAR | ||
| Mar 28, 2024 | Other acquisition or disposition (see the filing) Non-Voting Common Stock | +221,426 | 6,743,321 By Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Jan 29, 2024 | Other acquisition or disposition (see the filing) | −892,529 | 0 By Fairmount Healthcare Co-Invest II LP | Filing · EDGAR | ||
| Jan 29, 2024 | Other acquisition or disposition (see the filing) | +51,166 | 51,166 By Tomas Kiselak | Filing · EDGAR | ||
| Jan 29, 2024 | Other acquisition or disposition (see the filing) | +51,166 | 51,166 By Peter Harwin | Filing · EDGAR | ||
| Jul 13, 2023 | Open-market or private purchase | +55,913 | $17.00 | $951K | 55,913 By Fairmount Healthcare Fund LP | Filing · EDGAR |
| Jul 13, 2023 | Open-market or private purchase | +1,992,734 | $17.00 | $33.9M | 1,992,734 By Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Jul 13, 2023 | Open-market or private purchase | +892,529 | $17.00 | $15.2M | 892,529 By Fairmount Healthcare Co-Invest II LP | Filing · EDGAR |
| Jul 13, 2023 | Grant or award from the company Stock Option (Right to Buy) | +47,758 | 47,758 direct | Filing · EDGAR | ||
| Jul 13, 2023 | Grant or award from the company Stock Option (Right to Buy) | +47,758 | 47,758 direct | Filing · EDGAR |
Crescent Biopharma CBIO Director, 10% owner · filings 2025 to 2026 · bought $30.6M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jul 16, 2026 | Open-market or private purchase | +853,450 | $14.50 | $12.4M | 3,601,316 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR |
| Jul 16, 2026 | Open-market or private purchase Pre-Funded Warrant (Right to Buy) | +525,897 | $14.50 | $7.6M | 2,294,037 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR |
| Jun 2, 2026 | Grant or award from the company Stock Option (Right to Buy) | +11,050 | 11,050 By: Peter Harwin | Filing · EDGAR | ||
| Dec 4, 2025 | Open-market or private purchase | +1,360,000 | $13.41 | $18.2M | 2,747,866 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR |
| Dec 4, 2025 | Open-market or private purchase Pre-Funded Warrant (Right to Buy) | +131,434 | $13.41 | $1.8M | 1,768,140 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR |
| Jun 23, 2025 | Grant or award from the company Stock Option (Right to Buy) | +9,023 | 9,023 By: Peter Harwin | Filing · EDGAR |
Oruka Therapeutics ORKA Director, 10% owner · filings 2024 to 2026 · sold $300M · $300M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jul 1, 2026 | Derivative converted | +3,553,410 | 4,685,364 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR | ||
| Jul 1, 2026 | Open-market or private sale | −3,553,410 | $84.43 | $300M | 1,131,954 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR |
| Jul 1, 2026 | Derivative converted Series B Preferred Stock | −42,641 | 94,497 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR | ||
| Jun 2, 2026 | Grant or award from the company Stock Option (Right to Buy) | +9,136 | 9,136 By: Peter Harwin | Filing · EDGAR | ||
| Sep 17, 2025 | Grant or award from the company | +333,340 | $15.00 | $5M | 1,131,954 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR |
| Jun 2, 2025 | Grant or award from the company Stock Option (Right to Buy) | +17,500 | 17,500 By: Peter Harwin | Filing · EDGAR | ||
| Nov 19, 2024 | Option or RSU exercised or converted | +160,000 | $0.00 | $160 | 798,614 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR |
| Nov 19, 2024 | Option or RSU exercised or converted Series A Non-Voting Convertible Preferred Stock | −160 | 0 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR | ||
| Sep 11, 2024 | Grant or award from the company | +275,000 | $23.00 | $6.3M | 638,614 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR |
| Sep 11, 2024 | Grant or award from the company Series A Non-Voting Convertible Preferred Stock | +160 | $23,000.00 | $3.7M | 160 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR |
Spyre Therapeutics AGLE Director · filings 2023 to 2026 · sold $399.7M · $399.7M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 23, 2026 | Derivative converted | +666,680 | 4,684,781 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR | ||
| Jun 23, 2026 | Open-market or private sale | −4,684,781 | $85.31 | $399.7M | 0 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR |
| Jun 23, 2026 | Derivative converted Series B Preferred Stock | −16,667 | 0 Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| May 27, 2026 | Grant or award from the company Stock Option (Right to Buy) | +8,026 | 8,026 By Tomas Kiselak | Filing · EDGAR | ||
| May 29, 2025 | Grant or award from the company Stock Option (Right to Buy) | +25,000 | 25,000 By Peter Harwin | Filing · EDGAR | ||
| May 29, 2025 | Grant or award from the company Stock Option (Right to Buy) | +25,000 | 25,000 By Tomas Kiselak | Filing · EDGAR | ||
| May 14, 2024 | Grant or award from the company Stock Option (Right to Buy) | +11,323 | 11,323 By Peter Harwin | Filing · EDGAR | ||
| May 14, 2024 | Grant or award from the company Stock Option (Right to Buy) | +11,323 | 11,323 By Tomas Kiselak | Filing · EDGAR | ||
| Apr 25, 2024 | Option or RSU exercised or converted | +3,639,680 | 4,018,101 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR | ||
| Apr 25, 2024 | Option or RSU exercised or converted Series A Preferred Stock | −90,992 | 346,045 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR | ||
| Dec 29, 2023 | Other acquisition or disposition (see the filing) | −3,435,480 | 0 By Fairmount Healthcare Co-Invest L.P. | Filing · EDGAR | ||
| Dec 29, 2023 | Other acquisition or disposition (see the filing) | +406,038 | 406,038 By Tomas Kiselak | Filing · EDGAR | ||
| Dec 29, 2023 | Other acquisition or disposition (see the filing) | +406,038 | 406,038 By Peter Harwin | Filing · EDGAR | ||
| Dec 7, 2023 | Grant or award from the company Series B Preferred Stock | +16,667 | $600.00 | $10M | 16,667 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR |
| Nov 24, 2023 | Derivative converted | +3,435,480 | 3,435,480 By Fairmount Healthcare Co-Invest L.P. | Filing · EDGAR | ||
| Nov 24, 2023 | Derivative converted Series A Preferred Stock | −85,887 | 0 By Fairmount Healthcare Co-Invest L.P. | Filing · EDGAR |
Jade Biosciences JBIO Director, 10% owner · filings 2025 to 2026
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | Grant or award from the company Stock Option (Right to Buy) | +34,843 | 34,843 direct | Filing · EDGAR | ||
| Oct 6, 2025 | Grant or award from the company | +1,333,126 | $9.14 | $12.2M | 1,897,677 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR |
| Oct 6, 2025 | Grant or award from the company Pre-Funded Warrant (Right to Buy) | +855,047 | $9.14 | $7.8M | 855,047 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR |
| Apr 29, 2025 | Grant or award from the company Stock Option (Right to Buy) | +23,017 | 23,017 direct | Filing · EDGAR |
Viridian Therapeutics MGEN Director, 10% owner · filings 2020 to 2026 · bought $90M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| May 11, 2026 | Open-market or private purchase | +1,176,470 | $17.00 | $20M | 5,090,928 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR |
| Oct 23, 2025 | Open-market or private purchase | +454,545 | $22.00 | $10M | 3,914,458 Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Jun 10, 2025 | Option or RSU exercised or converted | +12,500 | $12.31 | $154K | 3,459,913 Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Jun 10, 2025 | Option or RSU exercised or converted Stock Option (Right to Buy) | −12,500 | 0 By: Peter Harwin | Filing · EDGAR | ||
| Jun 9, 2025 | Option or RSU exercised or converted | +1,600 | $7.80 | $12K | 3,447,413 Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Jun 9, 2025 | Option or RSU exercised or converted Stock Option (Right to Buy) | −1,600 | 0 By: Peter Harwin | Filing · EDGAR | ||
| Sep 13, 2024 | Open-market or private purchase | +1,600,000 | $18.75 | $30M | 3,445,813 Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Mar 28, 2024 | Other acquisition or disposition (see the filing) | −5,859 | 0 Fairmount Healthcare Fund LP | Filing · EDGAR | ||
| Mar 28, 2024 | Other acquisition or disposition (see the filing) | +5,859 | 1,845,813 Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Mar 28, 2024 | Other acquisition or disposition (see the filing) Series A Non-Voting Convertible Preferred Stock | −21,999 | 0 By Fairmount Healthcare Fund LP | Filing · EDGAR | ||
| Mar 28, 2024 | Other acquisition or disposition (see the filing) Series A Non-Voting Convertible Preferred Stock | +21,999 | 133,191 By Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Jan 22, 2024 | Open-market or private purchase | +476,190 | $21.00 | $10M | 1,839,954 Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Oct 30, 2023 | Grant or award from the company Series B Non-Voting Convertible Preferred Stock | +48,463 | $825.37 | $40M | 48,463 By Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Aug 17, 2022 | Open-market or private purchase | +425,531 | $23.50 | $10M | 1,363,764 Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Sep 21, 2021 | Open-market or private purchase | +909,000 | $11.00 | $10M | 938,233 Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Oct 30, 2020 | Open-market or private purchase Series A Non-Voting Convertible Preferred Stock | +5,494 | $465.96 | $2.6M | 21,999 Fairmount Healthcare Fund LP | Filing · EDGAR |
| Oct 30, 2020 | Open-market or private purchase Series A Non-Voting Convertible Preferred Stock | +28,843 | $465.96 | $13.4M | 111,192 Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Oct 27, 2020 | Other acquisition or disposition (see the filing) | +87,891 | 87,891 Fairmount Healthcare Fund LP | Filing · EDGAR | ||
| Oct 27, 2020 | Other acquisition or disposition (see the filing) | +438,502 | 438,502 Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Oct 27, 2020 | Other acquisition or disposition (see the filing) Series A Non-Voting Convertible Preferred Stock | +16,505 | 16,505 Fairmount Healthcare Fund LP | Filing · EDGAR | ||
| Oct 27, 2020 | Other acquisition or disposition (see the filing) Series A Non-Voting Convertible Preferred Stock | +82,349 | 82,349 Fairmount Healthcare Fund II LP | Filing · EDGAR |
Zenas BioPharma ZBIO Director · filings 2024 to 2026 · bought $14.1M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | Open-market or private purchase | +150,000 | $20.00 | $3M | 2,359,025 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR |
| Oct 7, 2025 | Open-market or private purchase | +316,219 | $19.00 | $6M | 2,209,025 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR |
| Jun 10, 2025 | Grant or award from the company Stock Option (Right to Buy) | +18,500 | 18,500 By Tomas Kiselak | Filing · EDGAR | ||
| Sep 16, 2024 | Derivative converted | +41,130 | 329,045 By Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Sep 16, 2024 | Derivative converted | +252,890 | 581,935 By Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Sep 16, 2024 | Derivative converted | +709,794 | 1,291,729 By Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Sep 16, 2024 | Derivative converted | +301,077 | 1,592,806 By Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Sep 16, 2024 | Open-market or private purchase | +300,000 | $17.00 | $5.1M | 1,892,806 By Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Sep 16, 2024 | Derivative converted Series Seed Convertible Preferred Stock | −357,143 | 0 By Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Sep 16, 2024 | Derivative converted Series A Convertible Preferred Stock | −2,195,871 | 0 By Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Sep 16, 2024 | Derivative converted Series B Convertible Preferred Stock | −6,163,236 | 0 By Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Sep 16, 2024 | Derivative converted Series C Convertible Preferred Stock | −2,614,287 | 0 By Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Sep 12, 2024 | Grant or award from the company Stock Option (Right to Buy) | +37,000 | 37,000 By Tomas Kiselak | Filing · EDGAR |
Cogent Biosciences UMRX Director · filings 2020 to 2026 · sold $370M · bought $44.5M · $370M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | Derivative converted | +7,000,000 | 12,503,418 Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Mar 31, 2026 | Open-market or private sale | −7,000,000 | $34.66 | $242.6M | 5,503,418 Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Mar 31, 2026 | Derivative converted Series A Convertible Preferred Stock | −28,000 | 39,414 Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Jan 22, 2026 | Open-market or private sale | −3,500,000 | $36.40 | $127.4M | 5,503,418 Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Jul 10, 2025 | Open-market or private purchase | +2,777,777 | $9.00 | $25M | 9,003,418 Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Jun 10, 2024 | Option or RSU exercised or converted | +1,500,000 | $0.00 | $2K | 6,225,641 Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Jun 10, 2024 | Option or RSU exercised or converted Series B Convertible Preferred Stock | −1,500 | 0 Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Mar 28, 2024 | Other acquisition or disposition (see the filing) | −286,851 | 0 Fairmount Healthcare Fund LP | Filing · EDGAR | ||
| Mar 28, 2024 | Other acquisition or disposition (see the filing) | +286,851 | 4,725,641 Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Mar 28, 2024 | Other acquisition or disposition (see the filing) Series A Convertible Preferred Stock | −11,914 | 0 Fairmount Healthcare Fund LP | Filing · EDGAR | ||
| Mar 28, 2024 | Other acquisition or disposition (see the filing) Series A Convertible Preferred Stock | +11,914 | 67,414 Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Feb 16, 2024 | Grant or award from the company | +1,166,666 | $7.50 | $8.7M | 4,438,790 Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Feb 16, 2024 | Grant or award from the company Series B Convertible Preferred Stock | +1,500 | $7,500.00 | $11.3M | 1,500 Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Jun 9, 2023 | Open-market or private purchase | +800,000 | $12.00 | $9.6M | 3,272,124 Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Jun 16, 2022 | Open-market or private purchase | +1,200,000 | $8.25 | $9.9M | 2,472,124 Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Jul 9, 2020 | Open-market or private purchase Series A Convertible Preferred Stock | +3,692 | $880.00 | $3.2M | 11,914 Fairmount Healthcare Fund LP | Filing · EDGAR |
| Jul 9, 2020 | Open-market or private purchase Series A Convertible Preferred Stock | +19,035 | $880.00 | $16.8M | 55,500 Fairmount Healthcare Fund II LP | Filing · EDGAR |
| Jul 6, 2020 | Other acquisition or disposition (see the filing) | +1,147,406 | 1,147,406 Fairmount Healthcare Fund LP | Filing · EDGAR | ||
| Jul 6, 2020 | Other acquisition or disposition (see the filing) | +5,088,497 | 5,088,497 Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Jul 6, 2020 | Other acquisition or disposition (see the filing) Series A Convertible Preferred Stock | +8,222 | 8,222 Fairmount Healthcare Fund LP | Filing · EDGAR | ||
| Jul 6, 2020 | Other acquisition or disposition (see the filing) Series A Convertible Preferred Stock | +36,465 | 36,465 Fairmount Healthcare Fund II LP | Filing · EDGAR |
Damora Therapeutics GLTO Director, 10% owner · filings 2025 to 2026
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Mar 23, 2026 | Grant or award from the company Stock Option (right to buy) | +37,313 | 37,313 By: Peter Harwin | Filing · EDGAR | ||
| Feb 9, 2026 | Option or RSU exercised or converted | +5,809,000 | 5,809,000 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR | ||
| Feb 9, 2026 | Option or RSU exercised or converted | +2,904,000 | 2,904,000 By Fairmount Healthcare Co-Invest V L.P. | Filing · EDGAR | ||
| Feb 9, 2026 | Option or RSU exercised or converted Series C Preferred Stock | −5,809 | 1,148 By Fairmount Healthcare Fund II L.P. | Filing · EDGAR | ||
| Feb 9, 2026 | Option or RSU exercised or converted Series C Preferred Stock | −2,904 | 574 By Fairmount Healthcare Co-Invest V L.P. | Filing · EDGAR |
Dianthus Therapeutics Director · filings 2023 to 2024 · bought $1.4M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Sep 27, 2024 | Other acquisition or disposition (see the filing) | −62,146 | 0 By Fairmount SPV III, LLC | Filing · EDGAR | ||
| May 23, 2024 | Grant or award from the company Stock Option (Right to Buy) | +11,000 | 11,000 See footnote | Filing · EDGAR | ||
| Apr 1, 2024 | Other acquisition or disposition (see the filing) | −58,857 | 0 By Fairmount Healthcare Fund LP | Filing · EDGAR | ||
| Apr 1, 2024 | Other acquisition or disposition (see the filing) | +58,857 | 2,700,691 By Fairmount Healthcare Fund II LP | Filing · EDGAR | ||
| Jan 22, 2024 | Grant or award from the company | +834,334 | $12.00 | $10M | 2,762,837 See footnote | Filing · EDGAR |
| Jan 22, 2024 | Grant or award from the company Pre-Funded Warrants (Right to Buy) | +832,333 | $12.00 | $10M | 832,333 See footnote | Filing · EDGAR |
| Sep 29, 2023 | Open-market or private purchase | +24,670 | $13.63 | $336K | 1,928,503 See footnote | Filing · EDGAR |
| Sep 26, 2023 | Open-market or private purchase | +30,000 | $13.15 | $395K | 1,903,833 See footnote | Filing · EDGAR |
| Sep 19, 2023 | Open-market or private purchase | +30,000 | $13.20 | $396K | 1,873,833 See footnote | Filing · EDGAR |
| Sep 13, 2023 | Open-market or private purchase | +9,367 | $11.76 | $110K | 1,843,833 See footnote | Filing · EDGAR |
| Sep 12, 2023 | Open-market or private purchase | +14,887 | $10.85 | $162K | 1,834,466 See footnote | Filing · EDGAR |
| Sep 11, 2023 | Grant or award from the company Stock Option (Right to Buy) | +6,500 | 6,500 See footnote | Filing · EDGAR |
All 84 Forms 3, 4, 5 and 144
| Filed | Form | Company | Links |
|---|---|---|---|
| Oct 15, 2026 | Form 3 | Alaunos Therapeutics TCRT | Filing · EDGAR |
| Sep 10, 2026 | Form 4 | Korsana Biosciences KRSA | Filing · EDGAR |
| Sep 10, 2026 | Form 3 | Korsana Biosciences KRSA | Filing · EDGAR |
| Sep 3, 2026 | Form 4 | Apogee Therapeutics APGE | Filing · EDGAR |
| Aug 11, 2026 | Form 4 | Apogee Therapeutics APGE | Filing · EDGAR |
| Jul 20, 2026 | Form 4 | Crescent Biopharma CBIO | Filing · EDGAR |
| Jul 1, 2026 | Form 144 | Oruka Therapeutics ORKA | Filing · EDGAR |
| Jul 1, 2026 | Form 4 | Oruka Therapeutics ORKA | Filing · EDGAR |
| Jun 23, 2026 | Form 144 | Spyre Therapeutics AGLE | Filing · EDGAR |
| Jun 23, 2026 | Form 4 | Spyre Therapeutics AGLE | Filing · EDGAR |
| Jun 11, 2026 | Form 4 | Jade Biosciences JBIO | Filing · EDGAR |
| Jun 11, 2026 | Form 4 | Apogee Therapeutics APGE | Filing · EDGAR |
| Jun 3, 2026 | Form 4 | Crescent Biopharma CBIO | Filing · EDGAR |
| Jun 3, 2026 | Form 4 | Oruka Therapeutics ORKA | Filing · EDGAR |
| May 29, 2026 | Form 4 | Spyre Therapeutics AGLE | Filing · EDGAR |
| May 13, 2026 | Form 4 | Viridian Therapeutics MGEN | Filing · EDGAR |
| Apr 1, 2026 | Form 4 | Zenas BioPharma ZBIO | Filing · EDGAR |
| Mar 31, 2026 | Form 144 | Cogent Biosciences UMRX | Filing · EDGAR |
| Mar 31, 2026 | Form 4 | Cogent Biosciences UMRX | Filing · EDGAR |
| Mar 25, 2026 | Form 4 | Damora Therapeutics GLTO | Filing · EDGAR |
| Feb 12, 2026 | Form 4 | Damora Therapeutics GLTO | Filing · EDGAR |
| Jan 22, 2026 | Form 4 | Cogent Biosciences UMRX | Filing · EDGAR |
| Jan 22, 2026 | Form 4 | Apogee Therapeutics APGE | Filing · EDGAR |
| Jan 22, 2026 | Form 144 | Cogent Biosciences UMRX | Filing · EDGAR |
| Jan 22, 2026 | Form 144 | Apogee Therapeutics APGE | Filing · EDGAR |
| Dec 8, 2025 | Form 4 | Crescent Biopharma CBIO | Filing · EDGAR |
| Nov 17, 2025 | Form 3 | Damora Therapeutics GLTO | Filing · EDGAR |
| Oct 27, 2025 | Form 4 | Viridian Therapeutics MGEN | Filing · EDGAR |
| Oct 9, 2025 | Form 4 | Zenas BioPharma ZBIO | Filing · EDGAR |
| Oct 8, 2025 | Form 4 | Jade Biosciences JBIO | Filing · EDGAR |
| Sep 19, 2025 | Form 4 | Oruka Therapeutics ORKA | Filing · EDGAR |
| Jul 14, 2025 | Form 4 | Cogent Biosciences UMRX | Filing · EDGAR |
| Jun 23, 2025 | Form 4 | Crescent Biopharma CBIO | Filing · EDGAR |
| Jun 23, 2025 | Form 3 | Crescent Biopharma CBIO | Filing · EDGAR |
| Jun 20, 2025 | Form 4 | Apogee Therapeutics APGE | Filing · EDGAR |
| Jun 12, 2025 | Form 4 | Zenas BioPharma ZBIO | Filing · EDGAR |
| Jun 11, 2025 | Form 4 | Viridian Therapeutics MGEN | Filing · EDGAR |
| Jun 3, 2025 | Form 4 | Oruka Therapeutics ORKA | Filing · EDGAR |
| Jun 2, 2025 | Form 4 | Spyre Therapeutics AGLE | Filing · EDGAR |
| May 1, 2025 | Form 4 | Jade Biosciences JBIO | Filing · EDGAR |
| May 1, 2025 | Form 3 | Jade Biosciences JBIO | Filing · EDGAR |
| Nov 21, 2024 | Form 4 | Oruka Therapeutics ORKA | Filing · EDGAR |
| Oct 1, 2024 | Form 4 | Dianthus Therapeutics | Filing · EDGAR |
| Sep 17, 2024 | Form 4 | Viridian Therapeutics MGEN | Filing · EDGAR |
| Sep 17, 2024 | Form 4/A | Zenas BioPharma ZBIO | Filing · EDGAR |
| Sep 16, 2024 | Form 4 | Zenas BioPharma ZBIO | Filing · EDGAR |
| Sep 13, 2024 | Form 4 | Oruka Therapeutics ORKA | Filing · EDGAR |
| Sep 12, 2024 | Form 3 | Zenas BioPharma ZBIO | Filing · EDGAR |
| Sep 6, 2024 | Form 3 | Oruka Therapeutics ORKA | Filing · EDGAR |
| Jun 12, 2024 | Form 4 | Cogent Biosciences UMRX | Filing · EDGAR |
| Jun 7, 2024 | Form 4 | Apogee Therapeutics APGE | Filing · EDGAR |
| May 28, 2024 | Form 4 | Dianthus Therapeutics | Filing · EDGAR |
| May 16, 2024 | Form 4 | Spyre Therapeutics AGLE | Filing · EDGAR |
| Apr 25, 2024 | Form 4 | Spyre Therapeutics AGLE | Filing · EDGAR |
| Apr 1, 2024 | Form 4 | Apogee Therapeutics APGE | Filing · EDGAR |
| Apr 1, 2024 | Form 4 | Viridian Therapeutics MGEN | Filing · EDGAR |
| Apr 1, 2024 | Form 4 | Dianthus Therapeutics | Filing · EDGAR |
| Apr 1, 2024 | Form 4 | Cogent Biosciences UMRX | Filing · EDGAR |
| Feb 16, 2024 | Form 4 | Cogent Biosciences UMRX | Filing · EDGAR |
| Jan 31, 2024 | Form 4 | Apogee Therapeutics APGE | Filing · EDGAR |
| Jan 24, 2024 | Form 4 | Dianthus Therapeutics | Filing · EDGAR |
| Jan 24, 2024 | Form 4 | Viridian Therapeutics MGEN | Filing · EDGAR |
| Dec 29, 2023 | Form 4 | Spyre Therapeutics AGLE | Filing · EDGAR |
| Dec 11, 2023 | Form 4 | Spyre Therapeutics AGLE | Filing · EDGAR |
| Nov 28, 2023 | Form 4 | Spyre Therapeutics AGLE | Filing · EDGAR |
| Nov 1, 2023 | Form 4 | Viridian Therapeutics MGEN | Filing · EDGAR |
| Oct 3, 2023 | Form 4 | Dianthus Therapeutics | Filing · EDGAR |
| Sep 28, 2023 | Form 4 | Dianthus Therapeutics | Filing · EDGAR |
| Sep 21, 2023 | Form 4 | Dianthus Therapeutics | Filing · EDGAR |
| Sep 13, 2023 | Form 4 | Dianthus Therapeutics | Filing · EDGAR |
| Sep 13, 2023 | Form 3 | Dianthus Therapeutics | Filing · EDGAR |
| Jul 17, 2023 | Form 4 | Apogee Therapeutics APGE | Filing · EDGAR |
| Jul 13, 2023 | Form 3 | Apogee Therapeutics APGE | Filing · EDGAR |
| Jun 30, 2023 | Form 3 | Spyre Therapeutics AGLE | Filing · EDGAR |
| Jun 13, 2023 | Form 4 | Cogent Biosciences UMRX | Filing · EDGAR |
| Aug 19, 2022 | Form 4 | Viridian Therapeutics MGEN | Filing · EDGAR |
| Jun 21, 2022 | Form 4 | Cogent Biosciences UMRX | Filing · EDGAR |
| Sep 23, 2021 | Form 4 | Viridian Therapeutics MGEN | Filing · EDGAR |
| Oct 30, 2020 | Form 4 | Viridian Therapeutics MGEN | Filing · EDGAR |
| Oct 30, 2020 | Form 3 | Viridian Therapeutics MGEN | Filing · EDGAR |
| Oct 29, 2020 | Form 4 | Viridian Therapeutics MGEN | Filing · EDGAR |
| Jul 13, 2020 | Form 4 | Cogent Biosciences UMRX | Filing · EDGAR |
| Jul 8, 2020 | Form 4 | Cogent Biosciences UMRX | Filing · EDGAR |
| Jul 8, 2020 | Form 3 | Cogent Biosciences UMRX | Filing · EDGAR |
Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.